Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liwanli Innovation CoTPE:3054 +4.42%62 EV-to-EBITDA is 9.22 as of Aug. 29, 2026, which is 36% below its 10-year median of 14.50. GuruFocus rates TPE:3054 with a GF Score™ of 62/100 and a GF Value™ of NT$119.56 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 733 Drug Manufacturers companies, Liwanli Innovation Co ranks better than 67.12% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Liwanli Innovation Co's enterprise value is NT$3,863.2 Mil.
Liwanli Innovation Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$419.1 Mil. Therefore, Liwanli Innovation Co's EV-to-EBITDA for today is 9.22.
The historical rank and industry rank for Liwanli Innovation Co's EV-to-EBITDA or its related term are showing as below:
TPE:3054'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2799.85 Med: 14.5 Max: 140.61
Current: 9.21
During the past 13 years, the highest EV-to-EBITDA of Liwanli Innovation Co was 140.61. The lowest was -2799.85. And the median was 14.50.
TPE:3054's EV-to-EBITDA is ranked better than 67.12% of 733
companies
in the Drug Manufacturers industry
Industry Median: 13.06
vs TPE:3054: 9.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Liwanli Innovation Co (TPE:3054) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Liwanli Innovation Co's PE Ratio (TTM) for today is calculated as:
Liwanli Innovation Co's share price for today is NT$56.70.
Liwanli Innovation Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$4.820.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Liwanli Innovation Co EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Liwanli Innovation Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Liwanli Innovation Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liwanli Innovation Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liwanli Innovation Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Liwanli Innovation Co's EV-to-EBITDA falls into.
Liwanli Innovation Co's current Enterprise Value is NT$3,863.2 Mil.
Liwanli Innovation Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$419.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liwanli Innovation Co (TPE:3054) has a EV-to-EBITDA of 9.22 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Liwanli Innovation Co. This is 36% below median its historical median of 14.50. According to the industry distribution chart, Liwanli Innovation Co ranks #241 out of 733 companies in the Drug Manufacturers industry, placing it in the top 32.9%.
Is Liwanli Innovation Co's EV-to-EBITDA too high?
Liwanli Innovation Co's current EV-to-EBITDA of 9.22 is 36% below median its 10-year median of 14.50. The Drug Manufacturers industry median EV-to-EBITDA is 13.06. Liwanli Innovation Co's value of 9.22 is 29.4% below this industry median. Based on the distribution chart, Liwanli Innovation Co ranks #241 out of 733 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Liwanli Innovation Co has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liwanli Innovation Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Liwanli Innovation Co ranks #241 out of 733 companies for EV-to-EBITDA. This puts Liwanli Innovation Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.06. Liwanli Innovation Co's value of 9.22 is 29.4% below this benchmark. While the company's 10-year median is 14.50 vs. the industry median of 13.06, Liwanli Innovation Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.06, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liwanli Innovation Co's current EV-to-EBITDA of 9.22 is 29.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Liwanli Innovation Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liwanli Innovation Co's current EV-to-EBITDA is 9.22, which is 36% below median its own 10-year median of 14.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liwanli Innovation Co stock overvalued right now?
Based on GuruFocus' analysis, Liwanli Innovation Co (TPE:3054) is currently considered Possible Value Trap. The stock's GF Value™ is NT$119.56, compared to a current price of NT$56.70 — trading 52.6% below its estimated fair value. The current EV-to-EBITDA is 9.22, which is 36% below median its 10-year median of 14.50 and 29.4% below the Drug Manufacturers industry median of 13.06. Liwanli Innovation Co's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Liwanli Innovation Co (TPE:3054), the current EV-to-EBITDA is 9.22 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liwanli Innovation Co (TPE:3054) Overvalued in 2026?
Based on GuruFocus' analysis, Liwanli Innovation Co stock appears to be undervalued.
The current stock price of NT$56.70 is trading 52.6% below its estimated GF Value™ of NT$119.56.
GuruFocus considers Liwanli Innovation Co to be Possible Value Trap.
Key valuation signals for TPE:3054:
EV-to-EBITDA: 9.22 (36% below median its 10-year median of 14.50)
GF Value™: NT$119.56 vs. price of NT$56.70 (52.6% below fair value)
Industry Position: 29.4% below the Drug Manufacturers median (#241 of 733)
No single metric tells the full story. See the TPE:3054 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liwanli Innovation Co Ltd is engaged in the manufacture, wholesale, and retail of electronic materials and the sales of biotech products like drug nutrient products. The reportable segments of the company are distinguished by products; the electronic department is mainly engaged in the sale and after-sales service of computer peripherals, memory and other related products; and the biotechnology department is mainly engaged in the sales of biotechnology products. Maximum revenue is generated from its Electronics department. Geographically, it generates a majority of its revenue from Taiwan, followed by other regions.
62GF Score
Get the complete analysis for TPE:3054
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3054 has been successfully added to your 
